지난 10월 31일 ~ 11월 01일 네덜란드 암스테르담 Tides Europe 학회에서 에스티팜 사업본부장 최석우 전무가 올리고뉴클레오타이 CDMO 사업 관련 하여
'Exploring Excellence in Oligonucleotide CDMO services at ST Pharm' 라는 주제로 인터뷰를 진행하였습니다.
인터뷰 영상 많은 시청 부탁 드리겠습니다.
In Tides Europe 2023, Kris (Seokwoo) Choi, Head of Marketing & Business Development at ST Pharm, was interviewed under the title 'Exploring the World of Oligonucleotide CDMO with STPharm'
About STPharm
Curious about ST Pharm? We're a 40-year-old company specializing in API CDMO service, serving clients in Europe, US, and Japan. Our focus extends from small molecule APIs to oligonucleotides, mRNA, and LNP formulations.
Recent Company News
Last September, we ST Pharm successfully marked the completion of its groundbreaking ceremony, signaling a significant step forward in expanding its oligonucleotide manufacturing capacity and capabilities. the construction of the new oligonucleotide facility at ST Pharm Banwol Campus planned for completion in 2025
Distinguishing Oligonucleotide CDMO Services
ST Pharm stands out with fully backward integrated capabilities in oligonucleotide services. From nucleoside synthesis to downstream processes, we ensure high-profile GMP operations.
Challenges in Oligonucleotide CDMO Industry
Beyond technical challenges, diversifying key raw material sourcing channels is crucial. Achieving reasonable cost of goods is paramount for success in emerging modalities.
Global Trends and STPharm Positioning
The oligonucleotide market is on an upward trajectory, especially in the last five to seven years. ST Pharm positions itself by adapting to trends, welcoming new players, and supporting the ecosystem through collaboration and partnerships.
Collaboration and Partnership Opportunities
ST Pharm actively collaborates with research institutions and biotech companies. Open to partnerships, we ensure quality and capacity, fostering a healthy ecosystem for oligonucleotide therapeutics.
'Exploring Excellence in Oligonucleotide CDMO services at ST Pharm' 라는 주제로 인터뷰를 진행하였습니다.
인터뷰 영상 많은 시청 부탁 드리겠습니다.
In Tides Europe 2023, Kris (Seokwoo) Choi, Head of Marketing & Business Development at ST Pharm, was interviewed under the title 'Exploring the World of Oligonucleotide CDMO with STPharm'
About STPharm
Curious about ST Pharm? We're a 40-year-old company specializing in API CDMO service, serving clients in Europe, US, and Japan. Our focus extends from small molecule APIs to oligonucleotides, mRNA, and LNP formulations.
Recent Company News
Last September, we ST Pharm successfully marked the completion of its groundbreaking ceremony, signaling a significant step forward in expanding its oligonucleotide manufacturing capacity and capabilities. the construction of the new oligonucleotide facility at ST Pharm Banwol Campus planned for completion in 2025
Distinguishing Oligonucleotide CDMO Services
ST Pharm stands out with fully backward integrated capabilities in oligonucleotide services. From nucleoside synthesis to downstream processes, we ensure high-profile GMP operations.
Challenges in Oligonucleotide CDMO Industry
Beyond technical challenges, diversifying key raw material sourcing channels is crucial. Achieving reasonable cost of goods is paramount for success in emerging modalities.
Global Trends and STPharm Positioning
The oligonucleotide market is on an upward trajectory, especially in the last five to seven years. ST Pharm positions itself by adapting to trends, welcoming new players, and supporting the ecosystem through collaboration and partnerships.
Collaboration and Partnership Opportunities
ST Pharm actively collaborates with research institutions and biotech companies. Open to partnerships, we ensure quality and capacity, fostering a healthy ecosystem for oligonucleotide therapeutics.